Literature DB >> 24080662

Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010.

Ritu Banerjee1, Ari Robicsek, Michael A Kuskowski, Stephen Porter, Brian D Johnston, Evgeni Sokurenko, Veronika Tchesnokova, Lance B Price, James R Johnson.   

Abstract

We assessed Escherichia coli ST131 and its H30 and H30-Rx subclones for virulence genes, antimicrobial resistance, and extended-spectrum beta-lactamase (ESBL) type. Although both subclones were associated with ESBL production, H30-Rx isolates had higher resistance scores and were associated specifically with CTX-M-15. Three virulence genes (iha, sat, and iutA) were more prevalent among H30 than non-H30 ST131 isolates. Thus, the H30 and H30-Rx subclones are more antimicrobial resistant and have virulence profiles that are distinct from those of non-H30 ST131 isolates.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24080662      PMCID： PMC3837873          DOI： 10.1128/AAC.01604-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Rapid and simple detection of blaCTX-M genes by multiplex PCR assay.

Authors:  Li Xu; Vicki Ensor; Savita Gossain; Kathy Nye; Peter Hawkey
Journal:  J Med Microbiol       Date:  2005-12       Impact factor: 2.472

2.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

3.  Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans.

Authors:  Aylin Colpan; Brian Johnston; Stephen Porter; Connie Clabots; Ruth Anway; Lao Thao; Michael A Kuskowski; Veronika Tchesnokova; Evgeni V Sokurenko; James R Johnson
Journal:  Clin Infect Dis       Date:  2013-08-06       Impact factor: 9.079

4.  Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise.

Authors:  J R Johnson; A L Stell
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

5.  Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009.

Authors:  James R Johnson; Carl Urban; Scott J Weissman; James H Jorgensen; James S Lewis; Glen Hansen; Paul H Edelstein; Ari Robicsek; Timothy Cleary; Javier Adachi; David Paterson; John Quinn; Nancy D Hanson; Brian D Johnston; Connie Clabots; Michael A Kuskowski
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

6.  Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli.

Authors:  James R Johnson; Veronika Tchesnokova; Brian Johnston; Connie Clabots; Pacita L Roberts; Mariya Billig; Kim Riddell; Peggy Rogers; Xuan Qin; Susan Butler-Wu; Lance B Price; Maliha Aziz; Marie-Hélène Nicolas-Chanoine; Chitrita Debroy; Ari Robicsek; Glen Hansen; Carl Urban; Joanne Platell; Darren J Trott; George Zhanel; Scott J Weissman; Brad T Cookson; Ferric C Fang; Ajit P Limaye; Delia Scholes; Sujay Chattopadhyay; David C Hooper; Evgeni V Sokurenko
Journal:  J Infect Dis       Date:  2013-01-03       Impact factor: 5.226

7.  Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004.

Authors:  James R Johnson; Megan Menard; Brian Johnston; Michael A Kuskowski; Kim Nichol; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products.

Authors:  James R Johnson; Andrew C Murray; Abby Gajewski; Maureen Sullivan; Paula Snippes; Michael A Kuskowski; Kirk E Smith
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region.

Authors:  Johann D D Pitout; Lorraine Campbell; Deirdre L Church; Daniel B Gregson; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  GenAlEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research--an update.

Authors:  Rod Peakall; Peter E Smouse
Journal:  Bioinformatics       Date:  2012-07-20       Impact factor: 6.937
View more
  53 in total

1.  The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant Escherichia coli Infections in the United States (2011-2012).

Authors:  James R Johnson; Stephen Porter; Paul Thuras; Mariana Castanheira
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

2.  Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage.

Authors:  Gisele Peirano; Akke K van der Bij; Joshua L Freeman; Laurent Poirel; Patrice Nordmann; Michael Costello; Veronika L Tchesnokova; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 4.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  Antibiotic-resistant Klebsiella pneumoniae and Escherichia coli high-risk clones and an IncFII(k) mosaic plasmid hosting Tn1 (blaTEM-4) in isolates from 1990 to 2004.

Authors:  Irene Rodríguez; Ângela Novais; Felipe Lira; Aránzazu Valverde; Tânia Curião; José Luis Martínez; Fernando Baquero; Rafael Cantón; Teresa M Coque
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

6.  Rapid and specific detection, molecular epidemiology, and experimental virulence of the O16 subgroup within Escherichia coli sequence type 131.

Authors:  James R Johnson; Olivier Clermont; Brian Johnston; Connie Clabots; Veronika Tchesnokova; Evgeni Sokurenko; Adam F Junka; Beata Maczynska; Erick Denamur
Journal:  J Clin Microbiol       Date:  2014-02-05       Impact factor: 5.948

7.  Clinical epidemiology and molecular analysis of extended-spectrum-β-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648.

Authors:  Jatan Bahadur Sherchan; Kayoko Hayakawa; Tohru Miyoshi-Akiyama; Norio Ohmagari; Teruo Kirikae; Maki Nagamatsu; Masayoshi Tojo; Hiroshi Ohara; Jeevan B Sherchand; Sarmila Tandukar
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 8.  A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131.

Authors:  Ritu Banerjee; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

9.  The Role of AcrAB-TolC Efflux Pumps on Quinolone Resistance of E. coli ST131.

Authors:  N Atac; O Kurt-Azap; I Dolapci; A Yesilkaya; O Ergonul; M Gonen; F Can
Journal:  Curr Microbiol       Date:  2018-10-03       Impact factor: 2.188

10.  A Pilot Study of Chicago Waterways as Reservoirs of Multidrug-Resistant Enterobacteriaceae (MDR-Ent) in a High-Risk Region for Community-Acquired MDR-Ent Infection in Children.

Authors:  Latania K Logan; Liqing Zhang; Stefan J Green; Samuel Dorevitch; Gustavo A Arango-Argoty; Kendrick Reme; Emily Garner; Jared Aldstadt; Yvette J Johnson-Walker; Mary K Hayden; Robert A Weinstein; Amy Pruden
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.